摘要
目的评价前列腺素E1注射液治疗中、重度慢性乙型肝炎(CHB)的疗效和安全性。方法应用前瞻性随机分组,将80例中重度慢性乙型肝炎患者分为2组,试验组应用前列腺素E1注射液10μg,每天静脉点滴1次;对照组应用还原型谷胱甘肽600mg,每天静注1次,疗程均为4周,观察患者0周、2周、4周的临床表现、生化指标和不良事件发生的情况。结果应用2种药物治疗后临床症状如纳差、恶心、呕吐、腹胀、乏力、肝区疼痛均有明显改善,体征如肝性面容、肝掌、蜘蛛痣无变化,两组间比较差异无显著性(P>0.05)。治疗组肝功能指标如ALT、AST、TBil、DBil、ALB在治疗2周、4周均有显著改善(P<0.05),综合疗效评价显示其治愈率、有效率和无效率分别是40.0%、55.0%、5.0%与对照组相比,两组差别无统计学意义(P>0.05)。不良反应率为10%,与对照组相比,两组差别无统计学意义(P>0.05),主要的不良反应为局部红肿、静脉炎等局部刺激症状和恶心、呕吐等消化道症状,无严重不良反应发生。结论前列腺素E1注射液能显著改善中、重度慢性肝炎的临床症状和肝功能指标,不良反应少且轻微。
Objective To evaluate the efficacy and safety of Prostaglandin E1 injection in the treatment of midrange and severity chronic hepatitis B.Methods A randomized controlled prospective clinical trial was carried out.The patients of study group were treated by Prostaglandin E1 injection and the patients of control group were treated by reduced glutathione.The period of treatment was 4 weeks.Results The symptom such as anepithymia,nausea,vomiting,abdominal distention and debilitation were ameliorated and the physical sign such as liver complexion,liver palm,spider telangiectasia were not changed.The levels of ALT,AST,TBil,DBil and ALB were decreased at the end of two weeks and four weeks.At the end of treatment the cure,efficiency and inefficiency rate were 40.0%,55.0%,5.0%,respectively.The adverse effect rate is 10%.There is no significant of efficacy and adverse effect between the groups.Conclusions Prostaglandin E1 injection can improve the symptom and liver function index,its adverse effect is rare and light.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2007年第1期37-39,共3页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
